Brief Article
Copyright ©2012 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Sep 7, 2012; 18(33): 4542-4548
Published online Sep 7, 2012. doi: 10.3748/wjg.v18.i33.4542
Efficacy of a therapeutic strategy for eradication of Helicobacter pylori infection
Giuliana Sereni, Francesco Azzolini, Lorenzo Camellini, Debora Formisano, Francesco Decembrino, Veronica Iori, Cristiana Tioli, Maurizio Cavina, Francesco Di Mario, Giuliano Bedogni, Romano Sassatelli
Giuliana Sereni, Francesco Azzolini, Lorenzo Camellini, Francesco Decembrino, Veronica Iori, Cristiana Tioli, Maurizio Cavina, Giuliano Bedogni, Romano Sassatelli, Unit of Gastroenterology and Digestive Endoscopy, Arcispedale Santa Maria Nuova, Istituto di Ricovero e Cura a Carattere Scientifico, 42123 Reggio Emilia, Italy
Debora Formisano, Statistics and Clinical Epidemiology Unit, Arcispedale Santa Maria Nuova, Istituto di Ricovero e Cura a Carattere Scientifico, 42123 Reggio Emilia, Italy
Francesco Di Mario, Unit of Gastroenterology, Ospedale S. Maria di Ca’ Foncello, 31100 Treviso, Italy
Author contributions: Sereni G, Azzolini F, Camellini L, Decembrino F, Iori V, Tioli C, Cavina M and Sassatelli R treated and included the patients in the study and had access to the data; Azzolini F generated a computer-based database of all patients; Sereni G planned the study, organized and analyzed the data, discussed with all the authors the statistical analysis report and wrote the manuscript; Formisano D contributed to the statistical analysis of the data; Camellini L, Sassatelli R, Bedogni G and Di Mario F participated in the editing of the final report.
Correspondence to: Giuliana Sereni, MD, PhD, Unit of Gastroenterology and Digestive Endoscopy, Arcispedale Santa Maria Nuova, Istituto di Ricovero e Cura a Carattere Scientifico, Viale Risorgimento 80, 42123 Reggio Emilia, Italy. giuliana.sereni@asmn.re.it
Telephone: +39-522-296947 Fax: +39-522-295941
Received: December 31, 2011
Revised: April 16, 2012
Accepted: May 26, 2012
Published online: September 7, 2012
Abstract

AIM: To determine the efficacy of our therapeutic strategy for Helicobacter pylori (H. pylori) eradication and to identify predictive factors for successful eradication.

METHODS: From April 2006 to June 2010, we retrospectively assessed 2428 consecutive patients (1025 men, 1403 women; mean age 55 years, age range 18-92 years) with gastric histology positive for H. pylori infection referred to our unit for 13-C urea breath test (UBT), after first-line therapy with proton pump inhibitor (PPI) b.i.d. + amoxicillin 1 g b.i.d. + clarithromycin 500 mg b.i.d. for 7 d. Patients who were still positive to UBT were recommended a second-line therapy (PPI b.i.d. + amoxicillin 1 g b.i.d. + tinidazole 500 mg b.i.d. for 14 d). Third choice treatment was empirical with PPI b.i.d. + amoxicillin 1 g b.i.d. + levofloxacin 250 mg b.i.d. for 14 d.

RESULTS: Out of 614 patients, still H. pylori-positive after first-line therapy, only 326 and 19 patients respectively rechecked their H. pylori status by UBT after the suggested second and third-line regimens. “Per protocol” eradication rates for first, second and third-line therapy were 74.7% (95% CI: 72.7%-76.4%), 85.3% (95% CI: 81.1%-89.1%) and 89.5% (95% CI: 74.9%-103%) respectively. The overall percentage of patients with H. pylori eradicated after two treatments was 97.8% (95% CI: 97.1%-98.4%), vs 99.9% (95% CI: 99.8%-100%) after three treatments. The study found that eradication therapy was most effective in patients with ulcer disease (P < 0.05, P = 0.028), especially in those with duodenal ulcer. Smoking habits did not significantly affect the eradication rate.

CONCLUSION: First-line therapy with amoxicillin and clarithromycin produces an H. pylori eradication rate comparable or superior to other studies and second-line treatment can still be triple therapy with amoxicillin and tinidazole.

Keywords: Helicobacter pylori, Eradication treatment, Rescue therapy, Eradication rate, Triple therapy, First-line therapy, Second-line therapy